Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
United Internet AG
XETRA:UTDI
|
DE |
Tempest Therapeutics Inc
Stock-Based Compensation
Tempest Therapeutics Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
Stock-Based Compensation
$3.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Stock-Based Compensation
$217.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
28%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.
See Also
What is Tempest Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
3.9m
USD
Based on the financial report for Sep 30, 2025, Tempest Therapeutics Inc's Stock-Based Compensation amounts to 3.9m USD.
What is Tempest Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-11%
Over the last year, the Stock-Based Compensation growth was -24%. The average annual Stock-Based Compensation growth rates for Tempest Therapeutics Inc have been 40% over the past three years , -2% over the past five years , and -11% over the past ten years .
